OmniAb, Inc. Board of Directors

OmniAb, Inc., a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic, a bispecific rat, and OmniClic, a bispecific chicken, designed for discovery of bispecific antibody applications; OmniTaur, which provides unique structural characteristics of cow antibodies for complex targets; and OmniDeep, a suite of in silico, an AI and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities. OmniAb, Inc. was founded in 2012 and is headquartered in Emeryville, California.

Mr. Matthew W. Foehr

Mr. Matthew W. Foehr

President, CEO & Director

Dr. Douglas S. Krafte Ph.D.

Dr. Douglas S. Krafte Ph.D.

Senior VP of Ion Channels/Transporters & Icagen Ion Channel Technology Site Head

Dr. Bill Harriman Ph.D.

Dr. Bill Harriman Ph.D.

Senior Vice President of Antibody Discovery

Mr. Charles S. Berkman J.D.

Mr. Charles S. Berkman J.D.

Chief Legal Officer & Secretary

Ms. Cia McCaffrey

Ms. Cia McCaffrey

Vice President of People & Talent

Ms. Donna Ventura CPA

Ms. Donna Ventura CPA

Senior VP & Corporate Controller

Dr. Christel Iffland Ph.D.

Dr. Christel Iffland Ph.D.

Senior Vice President of Antibody Technologies

Mr. Kurt A. Gustafson

Mr. Kurt A. Gustafson

Executive VP of Finance & CFO

Ms. Marie-Cecile van de Lavoir D.V.M., Ph.D.

Ms. Marie-Cecile van de Lavoir D.V.M., Ph.D.

Senior Vice President of Technical Operations & Genetics

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.